HERO demonstrated that Orgovyx was superior to Lupron in maintaining castration from day 29 up to week 48. Orgovyx also showed an almost a five-fold reduction in the risk of subsequent major cardiac events, a concern for men on Lupron.
Relugolix - An Oral Lupron Like Drug – On The Horizon
Myovant Sciences has developed an alternative gonadotropin-releasing hormone (GnRH) antagonist named relugolix. Their still investigational treatment is an oral (taken by mouth) as opposed to an injectable gonadotropin-releasing hormone (GnRH) antagonist. It has completed a very successful phase III clinical trial called HERO has been submitted to the FDA for approval. We at Cancer ABCs believe relugolix will be approved by the FDA shortly.